Fig. 1
From: Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
XPO1 inhibitors suppress MYC protein expression in DHLs. a Changes in MYC protein level upon treatment with KPT8602 (1 μM for 24 h). Asterisk (*) indicates that DHL5 is not considered a DHL line. b Time-dependent modulation of MYC protein in three DHL cell lines upon exposure to KPT330 or KPT8602 for 4, 8, 12, and 24 h. Cells were treated with a drug concentration of 0.5 μM for DHL4/Toledo and 1 μM for DHL6. c Dose-dependent reduction of MYC protein level upon XPO1 inhibition. Cells were treated with 0 to 0.8 μM KPT330 or KPT8602 for 24 h. β-tubulin (Tub) serves as a loading control. d–e Changes in transcript levels of MYC targets upon XPO1 inhibition. DHL6 was treated with KPT8602 at 1 μM for 8 and 24 h. f Total mRNA and g nuclear to cytoplasmic ratios of MYC and β-tubulin transcripts in DHL6 treated with 1 μM of KPT8602 for 4, 16, or 24 h. All mRNA values were normalized to GAPDH